Aerie Pharmaceuticals, a RTP based biotech firm, recently announced the close of a $30M series B round of funding. As a discovery and development firm in the field of ophthalmology, this round will help Aerie further develop their portfolio of treatments for glaucoma. Aerie raised a total of $61M since inception.
Aerie joined the CED community in 2005. Tom van Haarlem, CEO of Aerie, spoke at CED’s Biotech Conference in February.
Read the full press release here
No comments:
Post a Comment